Can immunotherapy plus liver treatments open the door to transplants for more cancer patients?
NCT ID NCT07489976
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether combining immunotherapy drugs (tremelimumab and durvalumab) with liver-directed procedures like TACE, TARE, or RFA can shrink liver cancer enough to make patients eligible for a liver transplant. The trial enrolls 41 adults with hepatocellular carcinoma that is too advanced for standard transplant criteria. Researchers will track how many patients achieve successful downstaging within 12 months and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tremelimumab and Durvalumab (immunotherapy drugs) combined with liver-directed procedures (TACE, TARE, or RFA)
What this could lead to
If successful, this approach could help more people with advanced liver cancer become eligible for a life-saving liver transplant.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 41 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects, and the combination with liver procedures may increase risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars Sinai
RECRUITINGLos Angeles, California, 90048, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••